Premium
Role of programmed death‐ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous cell carcinoma
Author(s) -
Ueki Yushi,
Takahashi Takeshi,
Ota Hisayuki,
Shodo Ryusuke,
Yamazaki Keisuke,
Horii Arata
Publication year - 2020
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26374
Subject(s) - nivolumab , medicine , oncology , head and neck squamous cell carcinoma , chemotherapy , head and neck , salvage therapy , pd l1 , head and neck cancer , surgery , cancer , immunotherapy
Background It was reported that treatment outcomes of the salvage chemotherapy (SCT) following nivolumab are fairly good compared with those of nivolumab itself. However, predictive factors of SCT for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) were not determined. Methods Twenty‐one R/M HNSCC patients received SCT following nivolumab. The treatment outcome and predictive factors for the favorable response to SCT were investigated. Results The objective response rate (ORR) and the disease control rate of SCT were 52.4% and 81.0%, respectively. The median progression‐free survival and the median overall survival time were 5.4 and 12.9 months, respectively. Patients with positive programmed death‐ligand 1 (PD‐L1) expression showed greater tumor shrinkage evaluated by the response evaluation criteria in solid tumors and higher ORR than those with negative PD‐L1 expression. Conclusions Treatment outcome of SCT following nivolumab in R/M HNSCC was favorable. PD‐L1 expression may be a predictive factor of SCT.